A Snapshot of the Expression Signature of Androgen Receptor Splicing Variants and Their Distinctive Transcriptional Activities

被引:164
作者
Hu, Rong [1 ]
Isaacs, William B. [1 ,2 ]
Luo, Jun [1 ,2 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21287 USA
关键词
tiling microarray; androgen receptor splicing variant; castration-resistant prostate cancer; PROSTATE-CANCER PROGRESSION; CASTRATION RESISTANCE; ABIRATERONE ACETATE; BINDING; DOMAIN;
D O I
10.1002/pros.21382
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. The diversity and complexity of the human androgen receptor (AR) splicing variants are well appreciated but not fully understood. The goal of this study is to generate a comprehensive expression signature of AR variants in castration-resistant prostate cancer (CRPC), and to address the relative importance of the individual variants in conferring the castration-resistant phenotype. METHODS. A modified RNA amplification method, termed selective linear amplification of sense RNA, was developed to amplify all AR transcripts containing AR exon 3 in CRPC specimens, which were profiled using tiling expression microarrays. Coding sequences for the AR variants were cloned into expression vectors and assessed for their transcriptional activities. Quantitative RT-PCR was used to determine their in vivo expression patterns in an expanded set of clinical specimens. RESULTS. In addition to expression peaks in AR intron 3, a novel AR exon, termed exon 9, was discovered. Exon 9 was spliced into multiple novel AR variants. Different AR splicing variants were functionally distinctive, with some demonstrating constitutive activity while others were conditionally active. Conditionally active AR-Vs may activate AR signaling depending on the cellular context. Importantly, AR variant functions did not appear to depend on the full-length AR. CONCLUSIONS. This study provided the first unbiased snapshot of the AR variant signature consisting of multiple AR variants with distinctive functional properties, directly in CRPC specimens. Study findings suggest that the aggregate function of multiple AR variants may confer a castration-resistant phenotype independent of the full-length AR. Prostate 71:1656-1667, 2011. (C) 2011 Wiley-Liss, Inc.
引用
收藏
页码:1656 / 1667
页数:12
相关论文
共 25 条
  • [1] Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
    Andersen, Raymond J.
    Mawji, Nasrin R.
    Wang, Jun
    Wang, Gang
    Haile, Simon
    Myung, Jae-Kyung
    Watt, Kate
    Tam, Teresa
    Yang, Yu Chi
    Banuelos, Carmen A.
    Williams, David E.
    McEwan, Iain J.
    Wang, Yuzhou
    Sadar, Marianne D.
    [J]. CANCER CELL, 2010, 17 (06) : 535 - 546
  • [2] Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?
    Antonarakis, Emmanuel S.
    Eisenberger, Mario A.
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (01): : 12 - 13
  • [3] Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
    Attard, Gerhardt
    Reid, Alison H. M.
    A'Hern, Roger
    Parker, Christopher
    Oommen, Nikhil Babu
    Folkerd, Elizabeth
    Messiou, Christina
    Molife, L. Rhoda
    Maier, Gal
    Thompson, Emilda
    Olmos, David
    Sinha, Rajesh
    Lee, Gloria
    Dowsett, Mitch
    Kaye, Stan B.
    Dearnaley, David
    Kheoh, Thian
    Molina, Arturo
    de Bono, Johann S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) : 3742 - 3748
  • [4] Quantitative analysis of mRNA amplification by in vitro transcription
    Baugh, L. R.
    Hill, A. A.
    Brown, E. L.
    Hunter, Craig P.
    [J]. NUCLEIC ACIDS RESEARCH, 2001, 29 (05)
  • [5] BOVA GS, 1993, MODERN PATHOL, V6, P201
  • [6] Targeting the androgen receptor pathway in prostate cancer
    Chen, Yu
    Sawyers, Charles L.
    Scher, Howard I.
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2008, 8 (04) : 440 - 448
  • [7] Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target
    Chen, Yu
    Clegg, Nicola J.
    Scher, Howard I.
    [J]. LANCET ONCOLOGY, 2009, 10 (10) : 981 - 991
  • [8] Transcriptional maps of 10 human chromosomes at 5-nucleotide resolution
    Cheng, J
    Kapranov, P
    Drenkow, J
    Dike, S
    Brubaker, S
    Patel, S
    Long, J
    Stern, D
    Tammana, H
    Helt, G
    Sementchenko, V
    Piccolboni, A
    Bekiranov, S
    Bailey, DK
    Ganesh, M
    Ghosh, S
    Bell, I
    Gerhard, DS
    Gingeras, TR
    [J]. SCIENCE, 2005, 308 (5725) : 1149 - 1154
  • [9] Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance
    Dehm, Scott M.
    Schmidt, Lucy J.
    Heemers, Hannelore V.
    Vessella, Robert L.
    Tindall, Donald J.
    [J]. CANCER RESEARCH, 2008, 68 (13) : 5469 - 5477
  • [10] A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth
    Guo, Zhiyong
    Yang, Xi
    Sun, Feng
    Jiang, Richeng
    Linn, Douglas E.
    Chen, Hege
    Chen, Hegang
    Kong, Xiangtian
    Melamed, Jonathan
    Tepper, Clifford G.
    Kung, Hsing-Jien
    Brodie, Angela M. H.
    Edwards, Joanne
    Qiu, Yun
    [J]. CANCER RESEARCH, 2009, 69 (06) : 2305 - 2313